Women’s health is undergoing a long-overdue transformation. For decades, diagnostics have offered only fragments of the full picture — a few blood values here, a short consultation there. But as expectations shift and technology matures, a new standard is emerging: deep, multidimensional health intelligence that finally reflects the true complexity of the female body.

Viven, a fast-growing Nordic health-tech company, is at the forefront of this shift. With the launch of its new 360° Health Analysis, Viven introduces what may be the broadest women’s blood test on the market, now spanning more than 75 biomarkers, complete hormonal profiling, and a biological age assessment. But the real breakthrough lies in what happens after the data is collected.

Jenni Hyysalo is the medical chief and CEO of Viven, and Anni Ihamäki is the head of branding.

“When I saw the results, I was amazed. No lab test had ever given me such a clear view into my hormonal health with actionable advice. Viven is doing something important and genuinely new for women who want to take control of their well-being,” says Anni Ihamäki, partner in charge of branding.

Her reaction captures the essence of Viven’s approach. This is not just another diagnostic product. It is a full-system interpretation of a woman’s health that connects laboratory data with daily life. The analysis integrates blood values with symptoms, lifestyle habits, and personal goals, transforming isolated metrics into meaningful insight. Instead of receiving a list of numbers, the client receives a clear, structured picture of how her body is functioning and where attention is needed.

Most importantly, the process does not stop at interpretation. Each client receives a personalised, practical plan for improving wellbeing, covering lifestyle adjustments, nutritional guidance, tailored supplement protocols, and, when relevant, medical follow-up. A Viven physician reviews the results and provides professional recommendations, ensuring that the insights are not only understandable but clinically grounded. The customer is not left alone with data — she is given direction.

From data to direction: The rise of actionable health intelligence

The main problem with traditional health testing hasn’t been a lack of information. Instead, it has been a lack of translation. People are surrounded by health metrics yet underserved in guidance. Viven addresses this gap directly by turning complex biological data into clear next steps.

This shift from measurement to meaning is especially significant for modern women navigating fatigue, hormonal transitions, cycle irregularities, fertility questions, sleep challenges, weight changes, or long-term performance and well-being goals. In these moments, more data alone is not helpful. What matters is knowing what to do with it.

A new era in diagnostics reshapes women’s health

Although FemTech has grown rapidly in recent years, women’s health is still largely measured using frameworks designed for male biology. Hormonal fluctuations, life-stage transitions, and gender-specific symptoms are often overlooked or misunderstood in standard diagnostics.

Viven’s approach reverses that logic by placing female biology at the centre of the diagnostic system. By expanding both the scope and depth of analysis, the company aligns itself with a global shift toward personalised, proactive, preventive healthcare — a model in which women’s real experiences are no longer treated as anomalies, but as essential clinical data.

A new health standard for every woman

The upgraded 360° Health Analysis is designed for women at every life stage. It supports those who want to understand their hormonal balance in depth, prepare for pregnancy, investigate persistent fatigue or cycle challenges, strengthen energy and stress resilience, or take a truly proactive approach to long-term health.

Viven offers something rare and powerful: a comprehensive view of the body, professionally interpreted, and translated into a concrete plan forward.

A glimpse into the future of personal health

Viven’s 360° Health Analysis represents one of the clearest expressions of that future available today. It gives women the ability to understand their bodies with unprecedented depth — and to act on that understanding with confidence.

As healthcare moves from reactive treatment to proactive intelligence, solutions like Viven’s will define the new standard. 

|

|

Sponsored

Viven and the end of guesswork in women’s health: The rise of 360° health intelligence

Viven and the end of guesswork in women’s health: The rise of 360° health intelligence

In partnership with:

·

5 min read

Credit: Jenni Hyysalo, Viven

Credit: Jenni Hyysalo, Viven

Women’s health is undergoing a long-overdue transformation. For decades, diagnostics have offered only fragments of the full picture — a few blood values here, a short consultation there. But as expectations shift and technology matures, a new standard is emerging: deep, multidimensional health intelligence that finally reflects the true complexity of the female body.

Viven, a fast-growing Nordic health-tech company, is at the forefront of this shift. With the launch of its new 360° Health Analysis, Viven introduces what may be the broadest women’s blood test on the market, now spanning more than 75 biomarkers, complete hormonal profiling, and a biological age assessment. But the real breakthrough lies in what happens after the data is collected.

Jenni Hyysalo is the medical chief and CEO of Viven, and Anni Ihamäki is the head of branding.

“When I saw the results, I was amazed. No lab test had ever given me such a clear view into my hormonal health with actionable advice. Viven is doing something important and genuinely new for women who want to take control of their well-being,” says Anni Ihamäki, partner in charge of branding.

Her reaction captures the essence of Viven’s approach. This is not just another diagnostic product. It is a full-system interpretation of a woman’s health that connects laboratory data with daily life. The analysis integrates blood values with symptoms, lifestyle habits, and personal goals, transforming isolated metrics into meaningful insight. Instead of receiving a list of numbers, the client receives a clear, structured picture of how her body is functioning and where attention is needed.

Most importantly, the process does not stop at interpretation. Each client receives a personalised, practical plan for improving wellbeing, covering lifestyle adjustments, nutritional guidance, tailored supplement protocols, and, when relevant, medical follow-up. A Viven physician reviews the results and provides professional recommendations, ensuring that the insights are not only understandable but clinically grounded. The customer is not left alone with data — she is given direction.

From data to direction: The rise of actionable health intelligence

The main problem with traditional health testing hasn’t been a lack of information. Instead, it has been a lack of translation. People are surrounded by health metrics yet underserved in guidance. Viven addresses this gap directly by turning complex biological data into clear next steps.

This shift from measurement to meaning is especially significant for modern women navigating fatigue, hormonal transitions, cycle irregularities, fertility questions, sleep challenges, weight changes, or long-term performance and well-being goals. In these moments, more data alone is not helpful. What matters is knowing what to do with it.

A new era in diagnostics reshapes women’s health

Although FemTech has grown rapidly in recent years, women’s health is still largely measured using frameworks designed for male biology. Hormonal fluctuations, life-stage transitions, and gender-specific symptoms are often overlooked or misunderstood in standard diagnostics.

Viven’s approach reverses that logic by placing female biology at the centre of the diagnostic system. By expanding both the scope and depth of analysis, the company aligns itself with a global shift toward personalised, proactive, preventive healthcare — a model in which women’s real experiences are no longer treated as anomalies, but as essential clinical data.

A new health standard for every woman

The upgraded 360° Health Analysis is designed for women at every life stage. It supports those who want to understand their hormonal balance in depth, prepare for pregnancy, investigate persistent fatigue or cycle challenges, strengthen energy and stress resilience, or take a truly proactive approach to long-term health.

Viven offers something rare and powerful: a comprehensive view of the body, professionally interpreted, and translated into a concrete plan forward.

A glimpse into the future of personal health

Viven’s 360° Health Analysis represents one of the clearest expressions of that future available today. It gives women the ability to understand their bodies with unprecedented depth — and to act on that understanding with confidence.

As healthcare moves from reactive treatment to proactive intelligence, solutions like Viven’s will define the new standard. 

Board Programme

Built for Nordic listed company boards.

The only programme in the Nordics designed specifically for listed-company board work.
Five sessions, one cohort, twenty leaders in one room - Helsinki, 2026.

Board Programme

Built for Nordic listed company boards.

The only programme in the Nordics designed specifically for listed-company board work.
Five sessions, one cohort, twenty leaders in one room - Helsinki, 2026.

Topics

# Topics

Authors

Our editorial team includes Anu Ubaud, head of content, Anni Ihamäki, head of life content, and Emmi Laine, finance and business content lead.

Our editorial team includes Anu Ubaud, head of content, Anni Ihamäki, head of life content, and Emmi Laine, finance and business content lead.

Authors

Guest writer

Our editorial team includes Anu Ubaud, head of content, Anni Ihamäki, head of life content, and Emmi Laine, finance and business content lead.

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

Latest signalsLive feed
Moves trackerLive feed

Investor Event

Listeds Investor Event · Defence

Nordic defence is in a once-in-a-generation growth cycle. Eight listed and pre-IPO companies pitch to 100+ invited investors at Valkoinen Sali, Helsinki

21 September 2026

Latest on Listeds

Market Signals

Citycon approved a €422.6M sale of three Finnish shopping centres to a company controlled by G City's shareholders

Sep 15, 2026

Myyrmanni, Koskikeskus and Trio, classified as a related-party transaction and approved by the independent directors on 12 August. 

On 12 August 2026, Citycon Oyj's board approved the divestment of three Finnish shopping centres — Myyrmanni in Vantaa, Koskikeskus in Tampere and Trio in Lahti — at an appraisal value of approximately €422.6m, based on the 30 June 2026 valuation.

The buyer is Noga Finland Retail Properties Oy, which Citycon's release describes as controlled by the shareholders of G City Ltd. G City and its subsidiary Gazit Europe Netherlands B.V. held approximately 89.68 per cent of Citycon at the time. Citycon classified the transaction as a related-party transaction deviating from the ordinary course of business, and states that the independent board members approved it.

Completion is expected in the second half of 2026, conditional on a public offering of securities in Noga Retail Properties Ltd. and other customary conditions. Citycon may provide vendor financing of up to €84.5m at market terms, and retains asset and property management of the three centres after closing, for which it will receive management and success fees.

The numbers

Appraisal value of the three centres

approx. €422.6m

Against the 28 May LOI

approx. €400m at 31 March 2026 book value

Vendor financing Citycon may provide

up to €84.5m — about a fifth of the price

G City + Gazit at approval / after 31 August

89.68% 

Separate related-party facility, 13 May

up to €200m mutual on-call loan, repayable 15 February 2028

Governance and ownership

The transaction is the third disclosed related-party item between Citycon and its controlling owner in four months.

  • 13 May — Citycon's board approved a mutual on-call loan facility of up to €200m with G City, repayable by 15 February 2028, at interest set on arm's-length terms by an independent pricing agent. The release notes G City is Citycon's parent and a related party, and states the facility was approved unanimously by the independent board members.

  • 28 May — Citycon signed a non-binding letter of intent for the divestment of Finnish centres at a book value of around €400m as at 31 March 2026.

  • 12 August — The board approved the sale of the three centres at approximately €422.6m, again by decision of the independent board members.

The parking dispute, in date order

One of the three centres is at the centre of a public dispute in Finland this summer. The sequence, as reported:

  • July 2026 — Citycon cut free parking at Myyrmanni from two hours to one. Free parking was also shortened to one hour at Iso Omena and Lippulaiva in Espoo; a K-Citymarket merchant told Länsiväylä the conduct was classless.

  • 8 August — Espoo City Council chair Jarno Limnéll wrote in Länsiväylä that Citycon should re-evaluate the decision and enter genuine dialogue with entrepreneurs and customers, noting Iso Omena houses a library, pharmacy and health centre.

  • 12 August — The board approved the sale of all three centres.

  • 14 August — MP Mia Laiho, chair of the Länsi-Uusimaa wellbeing services county board, called for Citycon to come to the negotiating table over the one-hour limit at Iso Omena.

  • 4 September — Citycon extended free parking at Myyrmanni to 90 minutes. No change in Espoo 

These are separate decisions by the same company in the same weeks. 

What to watch

Completion of the €422.6m divestment depends on the public offering of Noga Retail Properties Ltd. securities, and the timing of that offering determines whether the transaction closes before or after Citycon leaves the exchange. G City commenced compulsory redemption proceedings on 2 September, and Finnish redemption proceedings ran to a determined redemption price. The delisting application follows as soon as it is permitted under applicable law.



Executive Intelligence

Women hold 34.9% of Helsinki board seats. The chair's seat moved the other way.

Sep 14, 2026

The half in which the EU board gender directive fell due, measured against the Listeds board composition dataset. Women's share of board seats rose 1.3 points. The share of female chairs fell from 12.0% to 10.7%.

According to the Board Index — Finland H1 2026 study by Listeds and Admincontrol, women's share of board seats on Nasdaq Helsinki rose from 33.6% to 34.9% over the first half of the year. The gain was 1.3 percentage points in six months, continuing the upward trend that began in 2022 (28.2%). 30 June 2026 was the compliance deadline for the EU directive on gender balance on the boards of listed companies (Directive (EU) 2022/2381). The largest single-year gain, however, came in 2025, when the share climbed 3.0 points from 30.6% to 33.6% — a full year before the deadline took effect.

The 40% target applies to a narrower group than the market average covers

The market-wide average still falls short of the directive's 40% target. The directive's obligations, however, apply only to companies above certain size thresholds — in Finland, more than 250 employees and either a balance sheet above €43 million or turnover above €50 million — whereas the Board Index figures cover the whole of Nasdaq Helsinki and the First North market. In the Large Cap segment, which comes closest to the group in scope, the threshold was passed: women held 42.0% of board seats at the end of June. Market-cap segment is an approximation rather than the legal test: some Mid Cap companies clear the employee and turnover thresholds, while a few Large Cap companies with small workforces do not. The lowest shares sit in small companies and on First North, which are largely outside the directive's scope.

One woman on the board is no longer enough

The change over the first half was not only a matter of volume. The emphasis shifted from appointing a first woman to filling more than one seat: the share of companies with only one woman on the board fell from 26.2% to 21.9%. At the same time, the share of companies where more than 40% of directors are women rose from 24.0% to 27.8%.

By segment, the largest step was taken in Small Cap companies, where women's share rose from 29.6% to 32.4%. First North remains the most male-dominated market segment: women hold just 27.5% of board seats there. By industry, the sharpest gains came in consumer staples (36.1% → 40.0%) and technology (29.5% → 32.9%). Real estate remains the least gender-diverse industry, with women at 25.0%.

Eight all-male boards — and fewer female chairs than before

One indicator stood still, the other turned down. The number of all-male boards remained at eight companies (4.4% → 4.3% of companies), and all of them are Small Cap or First North companies: Digitalist Group, Dovre Group, Eagle Filters Group, Norrhydro Group, Pallas Air, Summa Defence, Sunborn International and Titanium.

The share of female chairs fell from 12.0% (22 companies) to 10.7% (20 companies). Progress in board membership has therefore not yet reached the head of the table.

At the other end of the range, a group of companies has reached or passed gender parity. The highest shares of women were at Suominen (66.7%), Aktia Bank and Verkkokauppa.com (both 57.1%) and Huhtamäki (55.6%). Fiskars, Kempower, Orion, Stora Enso, Administer and Modulight landed at exactly 50%.

Internationalisation did not move at all

The nationality mix was entirely unchanged: Finnish nationals held 77.3% of board seats both at the start and at the close of the half. In every reading since 2022 the figure has sat between 77% and 78%. The only real movement in the series came in 2025, when the Finnish share fell from 78.2% to 77.3%.

Internationalisation is concentrated in a small number of large companies and in certain industries. The most international industries are telecommunications (44.1% Finnish), health care (61.9%) and energy (62.5%). Among market segments, Large Cap is the most international (58.4% Finnish). The most domestic industries are consumer staples (88.0%) and industrials (85.3%); among segments, Small Cap (87.8%) and First North (86.1%). The internationalisation of Finnish listed companies' business has not carried through to their board composition, and new listings still arrive on the exchange with largely all-domestic boards.

“Finnish listed companies are internationalising their business faster than their boards. If a company's growth comes from outside its home market, the board should include at least one director who has relevant business experience from that market. Today's digital board meeting systems make high-quality, frictionless board work possible across borders as well.”
Henrikki Hirvonen
Henrikki HirvonenCountry Manager Finland, Admincontrol

Average age edged down

The average age of boards fell from 57.6 to 57.0 years over the half. Across the full series, however, boards have aged: the average has risen from 55.7 years at the end of 2022, with the sharpest single move — up 1.1 years — in 2025 alone. Millennials (born 1980–1999) rose from 12.0% to 12.2% of board seats, and directors under 50 from 18.1% to 18.5%. The share of companies with no millennial director fell from 50.3% to 47.1%.

Even the youngest boards sit at or above 45 years of age. The only exception is Talenom, whose board has a calculated average age of 40.8 years and where 80.0% of directors are millennials.

Most of the adjustment came before the deadline, not because of it

Progress over the first half was broader than regulation alone requires, as shares also rose outside the directive's size thresholds. The open question is whether it continues without a deadline attached to it. The pattern in the data suggests much of the adjustment was anticipatory: the largest annual gain came in 2025, before the deadline, and the pace roughly halved in the half when compliance actually fell due.

“Diversity is measured by gender, nationality and age because those are measurable. A board's real capability, however, is a question of expertise: does the board's expertise match the tactics and the strategy the company intends to execute over the coming years. Composition is only the starting point. Diverse board work is not automatically effective, because different perspectives produce better decisions only if the way the board works lets them reach the table.”
 Henrikki Hirvonen
Henrikki HirvonenCountry Manager Finland, Admincontrol

Summary

Metric

1 Jan 2026

30 Jun 2026

Women on boards

33.6%

34.9%

Boards with no women

4.4% (8 companies)

4.3% (8 companies)

Boards with only one woman

26.2%

21.9%

Boards above 40% women

24.0%

27.8%

Female board chairs

12.0%

10.7%

Finnish directors

77.3%

77.3%

Average board age

57.6

57.0

Millennial directors

12.0%

12.2%

Boards with no millennial

50.3%

47.1%

Read the full index: Board Index — Finland | H1 2026

Join our Pulse, Best-of-the-Week, and Weekend newsletters

Join our Pulse, Best-of-the-Week, and Weekend newsletters